Pharmacokinetic and Pharmacodynamic Comparison of Two Formulations of a Fixed-Dose Combination of Gemigliptin/Rosuvastatin 50/20 mg: A Randomized, Open-Label, Single-Dose, Two-Way Crossover Study

PURPOSE: A fixed-dose combination (FDC) of gemigliptin/rosuvastatin 50/20 mg as a monolayer tablet has been used to treat patients with both type 2 diabetes mellitus and dyslipidemia. To improve the stability of the FDC, a new FDC formulation as a bilayer tablet was developed. This study aimed to co...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Eunsol, Yoo, Hyounggyoon, Jang, In-Jin, Yu, Kyung-Sang, Lee, SeungHwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898221/
https://www.ncbi.nlm.nih.gov/pubmed/33628012
http://dx.doi.org/10.2147/DDDT.S288986

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898221/
https://www.ncbi.nlm.nih.gov/pubmed/33628012
http://dx.doi.org/10.2147/DDDT.S288986

Ejemplares similares